Last reviewed · How we verify
Baseline ART
Baseline ART works by suppressing the replication of the human immunodeficiency virus (HIV) through the inhibition of reverse transcriptase.
Baseline ART works by suppressing the replication of the human immunodeficiency virus (HIV) through the inhibition of reverse transcriptase. Used for Treatment of HIV-1 infection in adults and children, Prevention of mother-to-child transmission of HIV.
At a glance
| Generic name | Baseline ART |
|---|---|
| Also known as | ART |
| Sponsor | Frontier Biotechnologies Inc. |
| Drug class | Nucleoside reverse transcriptase inhibitors (NRTIs) |
| Target | Reverse transcriptase |
| Modality | Small molecule |
| Therapeutic area | Infectious Diseases |
| Phase | Phase 2 |
Mechanism of action
Baseline ART is a combination of antiretroviral drugs that target different stages of the HIV life cycle, preventing the virus from replicating and reducing the viral load in the body. This is achieved through the inhibition of reverse transcriptase, an enzyme essential for the replication of retroviruses like HIV.
Approved indications
- Treatment of HIV-1 infection in adults and children
- Prevention of mother-to-child transmission of HIV
Common side effects
- Nausea
- Fatigue
- Headache
- Diarrhea
- Abdominal pain
Key clinical trials
- Adaptation and Implementation of an Evidence-based Approach to Advance HIV Prevention and Care (NA)
- Imaging and Biopsy of People With HIV-1 Undergoing Analytic Treatment Interruption (PHASE2)
- Evaluation of Multiple Interventions to Improve HIV Treatment Outcomes Among People Who Inject Drugs in India (NA)
- Serological Testing and Treatment for Plasmodium Vivax Malaria: a Trial in Ethiopia and Madagascar (PHASE3)
- HIV Self-testing for Partners of HIV-uninfected Postpartum Women (NA)
- LetSync: Pilot Test of Mobile Health (mHealth) Intervention (NA)
- Prehabilitation for EOC, Fallopian Tube, Primary Peritoneal Carcinoma and Pancreatic Cancer w/ NACT (PHASE1, PHASE2)
- The T Cell Activator of Cell Killing ("TACK") IT ON" STUDY (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Baseline ART CI brief — competitive landscape report
- Baseline ART updates RSS · CI watch RSS
- Frontier Biotechnologies Inc. portfolio CI